Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab Plus Bevacizumab With Chemotherapy in EGFR-mutant NSCLC With Acquired Resistance
NCT04245085Phase 2Completed
- Sponsor
- ETOP IBCSG Partners Foundation
- Start
- Sep 2020
- Primary completion
- Jul 2024
- Modality
- Monoclonal Antibodies
- Countries
- 5
01
Overview
A Phase 2 trial of atezolizumab, bevacizumab in non-small cell lung cancer (NSCLC), sponsored by ETOP IBCSG Partners Foundation. Started Sep 2020; status: completed.
02
Drugs
atezolizumabbevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04245085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04245085.